Table 1.
Total (n = 233) | Individuals With VAT Data (n = 209) | Individuals With SAT Data (n = 125) | Individuals With VAT, SAT, and CT Data (n = 72) | |
---|---|---|---|---|
Sex, n (%) | ||||
Women | 82 (35) | 78 (32) | 36 (29) | 22 (31) |
Men | 151 (65) | 131 (68) | 89 (71) | 50 (69) |
Age, y | 63 (56–72) | 64 (55–72) | 63 (55–70) | 64 (54–70) |
BMI, kg/m2 | 26.1 (23.7–29.2) | 26.1 (23.7–29.2) | 26.6 (24.3–30.3) | 26.4 (24.2–28.8) |
VFA, cm2 | 167 (116–236) | 165 (110–232) | 175 (117–251) | 182 (116–253) |
SFA, cm2 | 206 (159–255) | 206 (158–256) | 209 (162–255) | 203 (161–255) |
CT scan availability, n (%) | 153 (66) | 137 (66) | 91 (73) | 72 (100) |
Weight change within 1 y before surgery (%) | −2.4 (−6.7 to 0) | −2.4 (−6.7 to 0) | −1.1 (−6.7 to 0) | −3.0 (−6.7 to 0) |
Weight change, data availability, n (%) | 209 (90) | 189 (90) | 112 (90) | 65 (90) |
Tumor site, n (%) | ||||
Colon | 108 (46) | 100 (48) | 54 (43) | 33 (46) |
Rectum | 125 (54) | 109 (52) | 71 (57) | 39 (54) |
Tumor stage, n (%) | ||||
I | 38 (16) | 32 (15) | 17 (14) | 8 (11) |
II | 77 (33) | 70 (33) | 37 (30) | 23 (32) |
III | 65 (28) | 59 (28) | 37 (30) | 24 (33) |
IV | 45 (19) | 41 (20) | 27 (22) | 17 (24) |
Carcinoma in situ or no malignancy | 8 (3) | 7 (3) | 7 (6) | 0 |
Neoadjuvant therapy, n (%) | ||||
Yes | 74 (32) | 64 (31) | 44 (35) | 25 (35) |
No | 159 (68) | 145 (69) | 81 (65) | 47 (65) |
Data presented as median (interquartile range) for continuous variables and frequency (percentage) for categorical variables.